# Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

> **NCT03698279** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 665 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)
- **BIOLOGICAL:** High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)
- **BIOLOGICAL:** High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
- **BIOLOGICAL:** Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)
- **BIOLOGICAL:** FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)

## Key facts

- **NCT ID:** NCT03698279
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-09
- **Primary completion:** 2019-10-16
- **Final completion:** 2019-10-16
- **Target enrollment:** 665 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03698279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03698279, "Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03698279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*